Calithera Biosciences to Present at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology Roundtable
September 22 2016 - 9:00AM
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage
pharmaceutical company focused on discovering and developing novel
small molecule drugs directed against tumor metabolism and tumor
immunology targets for the treatment of cancer, today announced it
will present at the Leerink Partners Immuno-Oncology Roundtable on
Thursday, September 29, 2016 at 8:30 a.m. Eastern Time in New York,
NY. The presentation will be webcast live and available for
replay for up to 90 days at www.calithera.com under the tab
Investors.
About Calithera Calithera Biosciences, Inc. is
a clinical-stage pharmaceutical company focused on discovering and
developing novel small molecule drugs directed against tumor
metabolism and tumor immunology targets for the treatment of
cancer. Calithera’s lead product candidate, CB-839, is a
potent, selective, reversible and orally bioavailable inhibitor of
glutaminase. CB-839 takes advantage of the pronounced dependency
many cancers have on the nutrient glutamine for growth and
survival. It is currently being evaluated in Phase 1/2 clinical
trials in combination with standard of care agents. CB-1158
is a first-in-class immuno-oncology metabolic checkpoint inhibitor
targeting arginase, a critical immunosuppressive enzyme responsible
for T-cell suppression by myeloid-derived suppressor cells.
Arginase depletes arginine, a nutrient that is critical for the
activation, growth and survival of the body’s cancer-fighting
immune cells, known as cytotoxic T-cells. CB-1158 is
currently in a Phase I clinical trial. Calithera is
headquartered in South San Francisco, California. For more
information about Calithera, please visit www.calithera.com.
Forward Looking StatementsThis news release
contains forward-looking statements by Calithera that involve risks
and uncertainties. Actual results may differ from Calithera’s
expectations and important factors that could cause actual results
to differ materially. Calithera’s product candidates may not
progress through clinical development or receive required
regulatory approvals within expected timelines or at all. In
addition, clinical trials may not confirm any safety, potency or
other product characteristics described or assumed in this press
release. Such product candidates may not be beneficial to patients
or successfully commercialized. The failure to meet expectations
with respect to any of the foregoing matters may have a negative
effect on Calithera’s stock price. Additional information
concerning these and other risk factors affecting Calithera’s
business can be found in Calithera’s most recent Quarterly Report
on Form 10-Q filed with the Securities and Exchange Commission, and
other periodic filings with the Securities and Exchange
Commission at www.sec.gov. These forward-looking statements
are not guarantees of future performance and speak only as of the
date hereof, and, except as required by law, Calithera disclaims
any obligation to update these forward-looking statements to
reflect future events or circumstances.
Contact:
Jennifer McNealey
ir@Calithera.com
650-870-1071
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Apr 2023 to Apr 2024